Although treatment with cytotoxic agents has produced modest survival improvement in
patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau …

Importance of the field: The epidermal growth factor receptor (EGFR) is a cell surface
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …

Pancreatic cancer is the fourth leading cause of cancer related death. The difficulty in
detecting pancreatic cancer at an early stage, aggressiveness and the lack of effective …

Erlotinib is a potent inhibitor of epidermal growth factor receptor tyrosine kinase and has
been demonstrated to treat advanced or metastatic non-small cell lung cancer to prolong …

Erlotinib (Tarceva) is an orally available selective small-molecule inhibitor of HER1/EGFR
tyrosine kinase with a 50% inhibitory concentration of 2 nM for purified tyrosine kinase. This …

Non–small cell lung cancer (NSCLC) with activating mutations in the epidermal growth
factor receptor (EGFR) responds to EGFR tyrosine kinase inhibitors such as erlotinib …

Background: The combination of the reversible epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) erlotinib with gemcitabine obtained FDA approval for treating …

The liver displays an outstanding wound healing and regenerative capacity unmatched by
any other organ. This reparative response is governed by a complex network of …

Erlotinib (Tarceva) is a small-molecule, orally dosed, anti-cancer drug that inhibits the
epidermal growth factor receptor. Randomized, controlled clinical studies have …

Sorafenib, the first-line systemic drug for advanced hepatocellular carcinoma (HCC), has
demonstrated limited benefits with very low response rates. Thus it is essential to investigate …